NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
IPO Year:
Exchange: NASDAQ
Website: neogenomics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/13/2025 | Buy → Hold | The Benchmark Company | |
| 12/10/2024 | $22.00 | Buy | Jefferies |
| 5/1/2024 | $26.00 | Buy | Craig Hallum |
| 12/29/2023 | $25.00 → $21.00 | Buy | BTIG Research |
| 8/21/2023 | $18.00 | Equal-Weight → Overweight | Stephens |
| 5/16/2023 | Outperform → Mkt Perform | Raymond James | |
| 5/9/2023 | $25.00 | Neutral → Buy | BTIG Research |
| 2/24/2023 | $20.00 | Hold → Buy | The Benchmark Company |
| 2/1/2023 | $15.00 | Hold → Buy | Needham |
| 8/26/2022 | Buy → Hold | The Benchmark Company |
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4/A - NEOGENOMICS INC (0001077183) (Issuer)
4/A - NEOGENOMICS INC (0001077183) (Issuer)
4/A - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
4 - NEOGENOMICS INC (0001077183) (Issuer)
Issued on behalf of Oncolytics Biotech Inc. USA News Group News Commentary VANCOUVER, BC, Jan. 15, 2025 /PRNewswire/ -- As 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in cancer research, including cutting-edge AI technologies, novel targeted therapies, and innovative cancer vaccines. With over 50 oncology drug approvals in 2024, including the first tumor-infiltrating lymphocyte cell therapy, this year holds great promise for precision medicine and immunotherapy. Amid growing expectations for an active year for biotech stocks in 2025, developers of new cancer therapies are already releasing impor
Long-Range Plan reflects 12-13% revenue growth annually Presentation and webcast at 43rd Annual J.P. Morgan Healthcare Conference today, Wednesday, January 15, at 1:30 p.m. PT / 4:30 p.m. ET NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading oncology testing services company, today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan. "We enter 2025 with our patient-centric strategy in place, focusing on product innovation, further optimization and expansion of our commercial organization, and enhancing operational efficiencies," said Chris Smith, chief executive officer of NeoGenomics. "Building on the strong momentum o
SEATTLE and FORT MYERS, Fla., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced a multi-year exclusive strategic commercial collaboration that will advance minimal residual disease (MRD) monitoring options for patients with select blood cancers. Adaptive's next-generation sequencing (NGS)-based clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test to detect MRD in lymphoid canc
Chris Smith to retire effective April 1, 2025; Board Member Tony Zook named incoming CEO Company reaffirms Fiscal 2024 financial guidance NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook, an independent board member since 2023, will assume the role of CEO at that time. "Chris has provided exceptional leadership for NeoGenomics, joining the Company at a critical time and exceeding all expectations in transforming NeoGenomics into a growth business," said Lynn Tetrault, Chair of the Board of Directo
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Chris Smith, Chief Executive Officer, will deliver a presentation followed by Q&A on Wednesday, January 15, at 1:30 p.m. PT/4:30 p.m. ET. The presentation will be webcast live and accessible online via this link. A replay will be available on the Investor Relations section of the Company's website at ir.neogenomics.com. About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help t
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced the recent publication of a new study in ESMO Open, demonstrating how circulating tumor DNA (ctDNA) in monitoring molecular residual disease (MRD) may enable earlier identification of disease recurrence for high-risk melanoma patients. Melanoma impacted over 100,000 patients in 2023; the majority (55%) were men. Locally advanced melanoma is a complex disease with a risk of relapse ranging from 39% in stage IIIA to approximately 70% in stage IIIC. The study, "Bespoke ctDNA for Longitudinal Detection of Molecular Residual Disease in High-Risk Melanoma Patients," was conducted alongside researchers from th
The company will showcase new insights into CNS lymphoma, myeloid malignancies, and gene fusions in acute myeloid leukemia NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting, booth #2347, in San Diego, December 7-10. The company will also feature its robust hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel. "Our research at ASH demonstrates that NeoGenomics continues to advance its leadership posi
The new CTO-H provides the largest, longest and deepest view of hematological diseases ever created — establishing a new standard for clinical research ConcertAI and NeoGenomics (NASDAQ:NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization. CTO-H provides a research data solution that is unprecedented in its scale, longitudinality and biomarker depth. CTO-H is a major outcome of the collaboration jointly announced on Jan. 8, 2024, and the more recent joint research completed and scheduled for presentation at the 2024 American Society of Hematology Meeting on Monday, Dec.
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada, November 19-23 (booth #830). The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurate treatment options for cancer patients. "Our presence at AMP 2024 underscores NeoGenomics' dedication to advancing cancer care through ongoing research in precision medicine," said Warren Stone, CCO of NeoGenomics. "By continuing to improve our methods and technologies, we aim to enhance outcomes and set new standards for oncology testing." NeoGeno
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors. "We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics," said Lynn Tetrault, Chairwoman of the Board of NeoGenomics. "We look forward to working together to support the company and improve patient care." The Board has elected Felicia Williams to join the Board as an independent director effective November 1, 2024. Felicia, former interim CFO of Macy's Inc. and Fellow for CEO Action for Racial Equa
The Benchmark Company downgraded NeoGenomics from Buy to Hold
Jefferies initiated coverage of NeoGenomics with a rating of Buy and set a new price target of $22.00
Craig Hallum resumed coverage of NeoGenomics with a rating of Buy and set a new price target of $26.00
BTIG Research reiterated coverage of NeoGenomics with a rating of Buy and set a new price target of $21.00 from $25.00 previously
Stephens upgraded NeoGenomics from Equal-Weight to Overweight and set a new price target of $18.00
Raymond James downgraded NeoGenomics from Outperform to Mkt Perform
BTIG Research upgraded NeoGenomics from Neutral to Buy and set a new price target of $25.00
The Benchmark Company upgraded NeoGenomics from Hold to Buy and set a new price target of $20.00
Needham upgraded NeoGenomics from Hold to Buy and set a new price target of $15.00
The Benchmark Company downgraded NeoGenomics from Buy to Hold
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G/A - NEOGENOMICS INC (0001077183) (Subject)
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
SC 13G - NEOGENOMICS INC (0001077183) (Subject)
8-K - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
10-Q - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
10-Q - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
S-8 - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
10-Q - NEOGENOMICS INC (0001077183) (Filer)
8-K - NEOGENOMICS INC (0001077183) (Filer)
Adjusted EBITDA Improves 305%; Fifth Consecutive Quarter of Positive Adjusted EBITDA; Increasing FY Guidance to $37-$40 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024. Third Quarter 2024 Highlights As Compared To Third Quarter 2023 Consolidated revenue increased 10% to $168 million Clinical Services revenue increased 14% to $146 million Advanced Diagnostics revenue decreased 10% to $22 million Net loss decreased 4% to $18 million Adjusted EBITDA increased 305% to positive $13 million "We delivered a strong third quarter, again gro
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior
Company will host business update call on Sept. 24, 2024, at 8:30 a.m. ET NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cleared the feasibility stage with a new version of its RaDaR® technology and has resolved litigation with Natera regarding RaDaR 1.0. The Company will host a business update conference call and webcast on Tuesday, Sept. 24, 2024, beginning at 8:30 a.m. Eastern Time. The accelerated progress of the new RaDaR technology provided the Company the opportunity to negotiate a resolution with Natera as to RaDaR 1.0. The settlement, while confidential, is not material t
Second Quarter Revenue Increased 12% to $165 Million Raising Revenue Guidance $655 to $667 Million and Adjusted EBITDA to $33 to $37 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its second-quarter results for the period ended June 30, 2024. Second Quarter 2024 Highlights As Compared To Second Quarter 2023 Consolidated revenue increased 12% to $165 million Clinical Services revenue increased 15% to $141 million Advanced Diagnostics revenue decreased 3% to $23 million Net loss decreased 23% to $19 million Adjusted EBITDA increased 630% to positive $11 million "The second quart
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior
First Quarter Revenue Increased 14% to $156 Million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights Consolidated revenue increased 14% to $156 million Clinical Services revenue increased 17% to $135 million Advanced Diagnostics revenue decreased 3% to $22 million Net loss decreased 12% to $27 million Adjusted EBITDA was positive $3 million, an increase of 149% or $11 million "NeoGenomics had a strong start to 2024, with first quarter revenue growth of 14% yea
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its first quarter 2024 financial results on Tuesday, April 30, 2024. Company management will host a webcast and conference call that morning at 8:30 a.m. Eastern Time to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (877) 545-0523 (domestic) or (973) 528-0016 (international) at least five minutes prior to the call. The part
Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023. Highlights Fourth quarter consolidated revenue increased 12% to $156 million; Full year consolidated revenue increased 16% to $592 million Fourth quarter Clinical Services revenue increased 20% to $130 million; Full year Clinical Services revenue increased 18% to $496 million Fourth quarter Advanced Diagnostics revenue decreased 17% to $25 million; Full year
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024. Company management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to
Third Quarter Revenue Increased 18% to $152 MillionFORT MYERS, FL / ACCESSWIRE / November 6, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2023 as compared to September 30, 2022.Third Quarter 2023 HighlightsQ3 2023 ResultsConsolidated revenue increased 18% to $152 millionClinical Services revenue increased 20% to $128 millionAdvanced Diagnostics revenue increased 8% to $24 millionNet loss decreased 50% to $19 millionAdjusted EBITDA increased 129% to positive $3 millionRaised Full-Year 2023 GuidanceRaised revenue guidance to a range of $585 million - $592 million,
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors. "We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenomics," said Lynn Tetrault, Chairwoman of the Board of NeoGenomics. "We look forward to working together to support the company and improve patient care." The Board has elected Felicia Williams to join the Board as an independent director effective November 1, 2024. Felicia, former interim CFO of Macy's Inc. and Fellow for CEO Action for Racial Equa
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year
FT. MYERS, FL / ACCESSWIRE / June 29, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors.The Board has elected three new independent board members to join the board effective June 29, 2023. Elizabeth Floegel, Chief Information & Digital Officer of Numotion, a complex rehabilitation technology provider, will be a member of the Audit & Finance and Compliance Committees. Neil Gunn, former Chief Executive Officer of IDbyDNA, a developer of metagenomic technology for infectious disease testing and pathogen surveillance which was
FT. MYERS, FL / ACCESSWIRE / November 7, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, has appointed David B. Perez - a veteran leader in medical devices and health care services - to serve on its Board of Directors, effective November 3, 2022."I am thrilled to welcome David to our Board of Directors. With his proven record in growing and scaling highly-regulated companies, David brings valuable experience and insights to NeoGenomics as the company continues to expand its testing and information services to transform cancer care," said Lynn Tetrault, Chair of the Board of NeoGenomics.With 40 years of global executive lead
FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Lynn Tetrault, Esq., the current Executive Chair and Principal Executive Officer, as Chair of the Board and Interim CEO as of May 12, 2022.Ms. Tetrault has been serving as Executive Chair since March when the Company's CEO agreed to step down. Ms. Tetrault was overseeing the Interim Office of the CEO to provide seamless leadership continuity and operational management of the Company while the Board conducts a search for the Company's permanent CEO."Lynn's leadershi
FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the appointment of Vishal Sikri as President and Chief Commercial Officer of Inivata and the departure of former President of Inivata Dr. Clive Morris. Vishal will officially join NeoGenomics on May 23, 2022 and Dr. Morris will assist in the leadership transition over an appropriate handover period.Vishal Sikri has over 20 years of experience in the somatic diagnostics space and most recently was President of Oncology at Invitae. Prior to Invitae, Vishal served as U.S. General Manager for Biocartis l
Board Appoints Executive Chair and Interim Office of the CEOAnticipates First Quarter Results Below Guidance and Withdraws 2022 GuidanceFT. MYERS, FL / ACCESSWIRE / March 28, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that the Board of Directors (the "Board") and Mark Mallon, Chief Executive Officer, have agreed that Mr. Mallon will step down as CEO and member of the Board, effective immediately. This mutual agreement was not the result of any disagreements about strategy with management or the Board, inappropriate action by CEO, or any violation of compan
FT. MYERS, FL / ACCESSWIRE / February 14, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has announced that Shashikant Kulkarni, M.S (Medicine)., Ph.D., MBA, FACMG will be joining the NeoGenomics executive team as Executive Vice President for Research & Development and Chief Scientific Officer on March 7th.Dr. Kulkarni most recently served as Chief Scientific Officer and Senior Vice President of Innovation and Emerging Business at Baylor Genetics. He also served as a tenured professor and Vice Chairman for Research in the number one Genetics Department in the US, Department of Molecular and
Inivata Appoints David Eberhard MD, PhD as Chief Medical Officer Research Triangle Park, NC, USA and Cambridge, UK, 13 December 2021 -- Inivata, a leader in liquid biopsy, today announced the appointment of David Eberhard MD, PhD as Chief Medical Officer (CMO). David will oversee the clinical and strategic development of Inivata's liquid biopsy tests with a particular focus on its RaDaR™ assay for the detection of minimal residual disease (MRD). David is a seasoned healthcare executive, bringing over 20 years' experience in the research and development of oncology therapeutics, biomarkers, and diagnostics. He joins Inivata from Illumina, where he served as Senior Medical Director, Oncol
FT MYERS, FL / ACCESSWIRE / December 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the appointment of David Eberhard MD, PhD as Chief Medical Officer (CMO) of its liquid biopsy focused subsidiary Inivata Limited ("Inivata"). David will report to Inivata President Clive Morris and will oversee the clinical and strategic development of Inivata's liquid biopsy tests with a particular focus on its RaDaR™ assay for the detection of minimal residual disease (MRD).David is a seasoned healthcare executive, bringing over 20 years' experience in the research and development of onc